Breaking Finance News

Zacks Investment Research disclosed Johnson & Johnson (NYSE:JNJ), boosting its stock price target to $133.00 earlier today

Yesterday Johnson & Johnson (NYSE:JNJ) traded 0.65% higher at $119.16. The company’s 50-day average is $121.04 and its two hundred day moving average is $115.74. With the last stock close up 2.49% relative to the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. Trading volume was was down over the average, with 5,814,900 shares of JNJ changing hands under the typical 6,667,970 shares..

Johnson & Johnson (NYSE:JNJ) had its target price raised to $133 by Zacks Investment Research in an issued report released 9/13/2016. The new target price implies a possible upside of 0.12% based on the company’s previous closing price.

Previously on 8/22/2016, Vetr Inc. reported on Johnson & Johnson(NYSE:JNJ) upped the target price from $0.00 to $124.21 that indicated a possible upside of 0.04%.

Performance Chart:

Johnson & Johnson (NYSE:JNJ)

A total of 18 brokers have released a report on the stock. Zero rate the stock a strong buy, 0 rate the company a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and lastly 0 analystsrate the stock as sell with a 12-month target of $117.44

Johnson & Johnson has a PE of 22 with a one-year low of $89.90 and a one-year high of $126.07 and has a total market value of $0.0.

General Company Details For Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, and Switzerland and the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *